Drug Trial Radar · NCT06856577
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
311
Actual
Start
Feb 28, 2025
Primary completion
Dec 22, 2026
Study completion Nov 23, 2030
Sponsor
- Lead sponsor
- Adverum Biotechnologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.
Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Wet AMD
Interventions
Ixo-vecGenetic
Ixo-vec will be administered intravitreally.
AfliberceptDrug
Aflibercept will be administered intravitreally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from Baseline in Best-Corrected Visual Acuity (BCVA) based on an average at Weeks 52 and 56Time frame: Baseline, Week 52 and Week 56
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
Adverum Clinical Site 223
Gilbert, Arizona
Adverum Clinical Site 178
Phoenix, Arizona
Adverum Clinical Site 126
Phoenix, Arizona
Adverum Clinical Site 229
Scottsdale, Arizona
Adverum Clinical Site 159
Tucson, Arizona
Adverum Clinical Site 198
Springdale, Arkansas
Adverum Clinical Site 109
Bakersfield, California
Adverum Clinical Site 100
Beverly Hills, California
Adverum Clinical Site 201
Campbell, California
Adverum Clinical Site 172
Encino, California
Adverum Clinical Site 169
Fullerton, California
Adverum Clinical Site 224
Huntington Beach, California
Adverum Clinical Site 215
Redlands, California
Adverum Clinical Site 164
Riverside, California
Adverum Clinical Site 140
Sacramento, California
Adverum Clinical Site 212
Sacramento, California
Adverum Clinical Site 175
Santa Barbara, California
Adverum Clinical Site 202
Torrance, California
Adverum Clinical Site 189
Walnut Creek, California
Adverum Clinical Site 200
Denver, Colorado
Adverum Clinical Site 116
Lakewood, Colorado
Adverum Clinical Site 165
Waterford, Connecticut
Adverum Clinical Site 184
Deerfield Beach, Florida
Adverum Clinical Site 176
Fort Lauderdale, Florida
Adverum Clinical Site 221
Fort Myers, Florida
Adverum Clinical Site 168
Jacksonville, Florida
Adverum Clinical Site 214
Lakeland, Florida
Adverum Clinical Site 213
Orlando, Florida
Adverum Clinical Site 230
Pensacola, Florida
Adverum Clinical Site 124
Pompano Beach, Florida
Adverum Clinical Site 183
South Miami, Florida
Adverum Clinical Site 120
St. Petersburg, Florida
Adverum Clinical Site 193
Tampa, Florida
Adverum Clinical Site 182
Augusta, Georgia
Adverum Clinical Site 179
Oak Forest, Illinois
Adverum Clinical Site 207
Oak Park, Illinois
Adverum Clinical Site 195
Carmel, Indiana
Adverum Clinical Site 205
Carmel, Indiana
Adverum Clinical Site 197
Hagerstown, Maryland
Adverum Clinical Site 204
Hagerstown, Maryland
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.